openPR Logo
Press release

Diffuse Large B-Cell Lymphoma Market is on Higher Demand 2017 - 2025

03-09-2018 05:08 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: TMR Research

Diffuse Large B-Cell Lymphoma Market is on Higher Demand 2017 -

Global Diffuse Large B-cell Lymphoma Market: Snapshot

Lymphoma is a type of cancer affecting the human lymphatic system, a part of our immune system. The development of lymphoma begins when a type of white bold cell, lymphocytes commence to divide in an uncontrolled manner. Although there are two chief kinds of lymphocytes, T lymphocytes and B lymphocytes, B cells tend to be responsible for most lymphomas. Diffuse large B-cell lymphoma (DLBCL) develop from B cells that are abnormal, larger sized cells which are different from healthy, normal B cells. These abnormal cells spread out diffusely all over the tumor, wiping out the lymph node’s normal structure.

More than 4,800 people in the U.K. are diagnosed with diffuse large B-cell lymphoma every year, according to the U.K. Lymphoma Association. The disease can occur at any age, affecting children as well. However, the aged population is at a higher risk of developing diffuse large B-cell lymphoma. Several patients initially notice painless lumps, usually in their neck, groin, or armpit. Apart from this, loss of appetite, itching, and fatigue are also some other common symptoms.

Request Sample Copy of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=494

The continuous development of novel treatments and drugs for treating diffuse large B-cell lymphoma via research and development is assisting the growth of the global market for diffuse large B-cell lymphoma. For instance, in May 2017, it was announced that a rare sub-type of DLBCL, primary mediastinal B-cell lymphoma, can be treated through the use of pembrolizumab, a PD-1 inhibitor. An evaluation of 18 participants with diffuse large B-cell lymphoma under KEYNOTE 013 revealed the safety and efficacy of pembrolizumab.

Diffuse Large B-Cell Lymphoma Market: Overview

With a noticeable rise in the prevalence of diffuse large B-cell lymphoma (DLBCL), the market for DLBCL market is witnessing strong growth across the world. Analysts expect the trend to remain so over the next few years, owing to the increasing number of elderly people, the most prone to DLBCL segment of the overall population.

Diffuse large B-cell lymphoma (DLBCL) is the most common form of non hodgkin lymphoma (NHL) and is the main reason behind more than 30% of the newly diagnosed cancer cases in the U.S. alone. The prevalence of this disease is increasing at an alarming rate, which is likely to fuel the demand for DLBCL treatments substantially in the near future, leading to a considerable market growth.

Request TOC of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=494

This research report offers a detailed evaluation of the global market for DLBCL on the basis of its current and historical performance. The prominent trends, growth drivers, challenges, opportunities, and the future prospects of this market have also been examined thoroughly while conducting this study. The main objective of this study is to assist the market participants in gaining a clear and deep insight into this market.

Diffuse Large B-Cell Lymphoma Market: Trends and Opportunities

The increasing incidence of DLBCL has fueled the demand for efficient therapies for its treatment across the world. With the ever-rising global geriatric population, the scenario is likely to remain more or less similar over the forthcoming years. In addition, the presence of a robust last stage pipeline of drugs ready for clinical trials and the increasing expenditure on healthcare are expected to boost this market tremendously in the years to come.

At present, the most efficient treatment for DLBCL available across the world is combination therapy that includes chemotherapy and monoclonal antibody-based drug Rituxan (rituximab). However, the development of other drugs is also taking place at a swift pace, with many of them being in various late-stage clinical trials. Alisertib (MLN8237), Bortezomib (Velcade), Brentuximab vedotin (Adcetris), Everolimus (Afinitor), Lenalidomide (Revlimid), Panobinostat, and Vorinostat (Zolinza) are some of the key pipelined projects, approval of which will gain advantages for this market in the forthcoming years.

Read Comprehensive Overview of Report @ https://www.tmrresearch.com/diffuse-large-b-cell-lymphoma-market

Diffuse Large B-Cell Lymphoma Market: Geographical Analysis

North America, followed by Europe, has surfaced as the leading contributor to the global market for DLBCL, thanks to the high prevalence of DLBCL, rising awareness level of people, and their increased disposable income. However, Asia Pacific is likely to emerge as the most promising regional market in the coming years. The strengthening economy and the improving healthcare infrastructure in this region are expected to act as the key driving force behind the growth of the Asia Pacific DLBCL market.

Diffuse Large B-Cell Lymphoma Market: Companies Mentioned in the Report

Some of the major players operating in this market are Amgen, Inc., AstraZeneca plc, Astellas Pharma, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Gilead Sciences, Inc., Genentech, Inc., Infinity Pharmaceuticals, Inc., MedImmune, LLC, Merck & Co., Inc., Novartis AG and Sanofi.

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Our savvy custom-built reports span a gamut of industries such as pharmaceuticals, chemicals and metals, food and beverages, and technology and media, among others. With actionable insights uncovered through in-depth research of the market, we try to bring about game-changing success for our clients.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Email: sales@tmrresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Diffuse Large B-Cell Lymphoma Market is on Higher Demand 2017 - 2025 here

News-ID: 970737 • Views: 147

More Releases from TMR Research

Environmental Health and Safety (EHS) Market Latest Report with Forecast to 2025 …
Global Environmental Health and Safety (EHS) Market: Snapshot Concerns regarding the rising levels of pollution and looming threat of global warming have escalated in the recent past and a number of countries, developed or developing, have come together to reduce these concerns. One of the primary reason of environmental damage is the poor compliance of regulatory by various companies, and governments are now bringing in stricter regulations, which in turn is
Water Purifier Market Highlights On Future Development 2025 | GE Corporation, Pe …
Global Water Purifier Market: Snapshot The global water purifier market is anticipated to testify the stand out dominance of new product launch in the vendor landscape as players constantly look to grab a major share while gaining a competitive edge over their challengers. Bluewater Group’s three new products launched in 2016 were deemed to help the company to strengthen its foothold in the market and attract more consumers. All of the
POS Printer Market Comprehensive Survey 2028
Global POS Printer Market: Overview With the ceaseless digitization of shopping and entertainment activities, receipt POS printers are increasingly becoming de facto for businesses for ease of transaction. The use of receipt POS printers in place of standard desktop printers directly results in savings for businesses. This is because receipt POS printers are compact in size, use less ink and paper, and easily fit on a table or anywhere else depending
Multi-Touch Marketing Attribution Software Market Growth and Restrain Factors An …
Global Multi-Touch Marketing Attribution Software Market: Overview Multi-touch marketing attribution software market is in its nascent stages of progress. The market prepares advertisers with a holistic understanding between various touch points and resulting final sales. Get Sample Copy of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=5052 The two approaches adopted in the multi-touch marketing attribution software market are first-source attribution and last touch attribution. As the name suggests, the first touch attribution devotes all credit to

All 5 Releases


More Releases for DLBCL

Diffuse Large B-Cell Lymphoma Market - Upcoming Development 2025 | Genentech, In …
Global Diffuse Large B-cell Lymphoma Market: Snapshot Lymphoma is a type of cancer affecting the human lymphatic system, a part of our immune system. The development of lymphoma begins when a type of white bold cell, lymphocytes commence to divide in an uncontrolled manner. Although there are two chief kinds of lymphocytes, T lymphocytes and B lymphocytes, B cells tend to be responsible for most lymphomas. Diffuse large B-cell lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market 2022 Vendors, Driving …
The research report shows the continuous growth over the years in Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market with market size, growth rate, driving & trending factors, market trends, opportunities and threats. Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics market report provides top vendors, geographical regions, revenue, types, application, end users. Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics market 2018-2022 provides market landscape, market sizing, buyers, suppliers, new entrants, market share, revenue, consumption,
Diffuse Large B-Cell Lymphoma Market trends and dynamics 2017 - 2025 : Genentech …
Global Diffuse Large B-cell Lymphoma Market: Snapshot Lymphoma is a type of cancer affecting the human lymphatic system, a part of our immune system. The development of lymphoma begins when a type of white bold cell, lymphocytes commence to divide in an uncontrolled manner. Although there are two chief kinds of lymphocytes, T lymphocytes and B lymphocytes, B cells tend to be responsible for most lymphomas. Diffuse large B-cell lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma Market Trends and Opportunities 2017 - 2025 : Infi …
Global Diffuse Large B-cell Lymphoma Market: Snapshot Lymphoma is a type of cancer affecting the human lymphatic system, a part of our immune system. The development of lymphoma begins when a type of white bold cell, lymphocytes commence to divide in an uncontrolled manner. Although there are two chief kinds of lymphocytes, T lymphocytes and B lymphocytes, B cells tend to be responsible for most lymphomas. Diffuse large B-cell lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma Market Sees Coherent Growth during 2025
Global Diffuse Large B-cell Lymphoma Market: Snapshot Lymphoma is a type of cancer affecting the human lymphatic system, a part of our immune system. The development of lymphoma begins when a type of white bold cell, lymphocytes commence to divide in an uncontrolled manner. Although there are two chief kinds of lymphocytes, T lymphocytes and B lymphocytes, B cells tend to be responsible for most lymphomas. Diffuse large B-cell lymphoma (DLBCL)
DLBCL receives FDA orphan drug designation for eFT508
US Food and Drug Administration has announced orphan drug designation to eFT508, a highly selective inhibitor of MNK1 and MNK2 for the treatment of diffuse large B-cell lymphoma. The drug is developed by eFFECTOR Therapeutics. The company has initiated to evaluate the safety, pharmacokinetics, pharmacodynamics and antitumor activity of the agent in patients with B-cell hematologic malignancies. The company also is conducting a phase 1/phase 2 dose-escalation trial of eFT508